Insmed | INSM - Cost Of Sales

Stock Price
149.86
Daily Change
-1.17 -0.77%
Monthly
-14.85%
Yearly
87.44%
Q1 Forecast
152.04

Insmed reported $30.9M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025